These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30275224)

  • 1. Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.
    Wada K; Kishi N; Kanayama N; Hirata T; Morimoto M; Konishi K; Imamura F; Teshima T; Ogawa K
    Anticancer Res; 2018 Oct; 38(10):5951-5958. PubMed ID: 30275224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy.
    Wang J; Zhou Z; Liang J; Feng Q; Xiao Z; Hui Z; Wang X; Lv J; Chen D; Zhang H; Ji Z; Cao J; Liu L; Jiang W; Men Y; Xu C; Dai J; Yin W; Wang L
    Oncologist; 2016 Dec; 21(12):1530-1537. PubMed ID: 27628491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.
    Rodrigues G; Oberije C; Senan S; Tsujino K; Wiersma T; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; DeRuyck K; De Dios NR; Warner A; Bradley JD; Palma DA
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):133-9. PubMed ID: 25835622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.
    Ramaekers BL; Joore MA; Lueza B; Bonastre J; Mauguen A; Pignon JP; Le Pechoux C; De Ruysscher DK; ; Grutters JP
    J Thorac Oncol; 2013 Oct; 8(10):1295-307. PubMed ID: 24457241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
    Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
    Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy followed by late-course accelerated hyperfractionated radiation therapy for locally advanced non-small-cell lung cancer: long-term results of a phase I/II clinical trial.
    Chen M; Chen YY; Bao Y; Xian CG; Liu GZ; Zhang L; Xu GC; Deng XW; Lu TX; Qian JY; Cui NJ
    Clin Lung Cancer; 2005 Mar; 6(5):304-9. PubMed ID: 15845182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.
    Sheu T; Heymach JV; Swisher SG; Rao G; Weinberg JS; Mehran R; McAleer MF; Liao Z; Aloia TA; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):850-7. PubMed ID: 25216859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer.
    Jaksic N; Chajon E; Bellec J; Corre R; Ricordel C; de Latour B; Lena H; Schick U; de Crevoisier R; Castelli J
    Radiat Oncol; 2018 Aug; 13(1):147. PubMed ID: 30103774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC).
    Baumann M; Herrmann T; Koch R; Matthiessen W; Appold S; Wahlers B; Kepka L; Marschke G; Feltl D; Fietkau R; Budach V; Dunst J; Dziadziuszko R; Krause M; Zips D;
    Radiother Oncol; 2011 Jul; 100(1):76-85. PubMed ID: 21757247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Treatment Time and Overall Survival in Locally Advanced Non-small Cell Lung Cancer.
    McMillan MT; Ojerholm E; Verma V; Higgins KA; Singhal S; Predina JD; Berman AT; Grover S; Robinson CG; Simone CB
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1142-1152. PubMed ID: 28721898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.
    Wang L; Correa CR; Zhao L; Hayman J; Kalemkerian GP; Lyons S; Cease K; Brenner D; Kong FM
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1383-90. PubMed ID: 18929449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer.
    Maguire PD; Marks LB; Sibley GS; Herndon JE; Clough RW; Light KL; Hernando ML; Antoine PA; Anscher MS
    J Clin Oncol; 2001 Feb; 19(3):705-11. PubMed ID: 11157021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of circulating transforming growth factor-beta1 level during radiation therapy are correlated with the prognosis of locally advanced non-small cell lung cancer.
    Zhao L; Ji W; Zhang L; Ou G; Feng Q; Zhou Z; Lei M; Yang W; Wang L
    J Thorac Oncol; 2010 Apr; 5(4):521-5. PubMed ID: 20130485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.
    Miller ED; Fisher JL; Haglund KE; Grecula JC; Xu-Welliver M; Bertino EM; He K; Shields PG; Carbone DP; Williams TM; Otterson GA; Bazan JG
    J Thorac Oncol; 2018 Mar; 13(3):426-435. PubMed ID: 29326090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer.
    Reddy JP; Tang C; Shih T; Kim B; Kim C; Nguyen QN; Welsh J; Benveniste M; Zhang J; Liao Z; Gomez DR
    Clin Lung Cancer; 2017 Mar; 18(2):141-148. PubMed ID: 27913215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
    Campeau MP; Herschtal A; Wheeler G; Mac Manus M; Wirth A; Michael M; Hogg A; Drummond E; Ball D
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1371-5. PubMed ID: 19250769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.